Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools Inc. (LAB)
Company Research
Source: GlobeNewswire
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed the previously announced sale of SomaLogic to Illumina, Inc. (NASDAQ: ILMN) (“Illumina”) for $350 million in upfront cash and up to $75 million in near-term earnout payments for aggregate cash consideration of up to $425 million plus specified royalties. “The closing of this transaction marks a major milestone in our strategic transformation. We are lean, focused and extremely well positioned, and emerge today far stronger than we were yesterday,” said Michael Egholm, PhD, Pr
Show less
Read more
Impact Snapshot
Event Time:
LAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LAB alerts
High impacting Standard BioTools Inc. news events
Weekly update
A roundup of the hottest topics
LAB
News
- Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Standard BioTools (NASDAQ:LAB) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 RevenueGlobeNewswire
- Standard BioTools: Outlook Still Murky [Seeking Alpha]Seeking Alpha
LAB
Earnings
- 8/11/25 - Miss
LAB
Sec Filings
- 1/30/26 - Form 8-K
- 1/8/26 - Form 8-K
- 1/7/26 - Form SCHEDULE
- LAB's page on the SEC website